Molecular Therapy Impact Factor

The first useful signal is that Molecular Therapy still sits very high in its field even after the pandemic-era citation cycle cooled. A 12.0 JIF in a mature therapeutic field means the journal remains one of the main owner venues for work that changes how researchers think about vectors, delivery, engineering, or therapeutic strategy.

The second useful signal is durability. The five-year JIF of 12.4 runs slightly above the current JIF, which is what you want to see in a field where good platform papers keep getting reused as reference points.

The third useful signal is trust. The JIF without self-cites is 11.8, very close to the headline number, and the JCI is 2.89. Together, those numbers say the journal is not living off internal citation behavior or one narrow citation niche.

The JCR row above is the authoritative impact factor on this page. For the longer directional view, the table below uses the open Scopus-based impact score series as a trend proxy.

Directionally, the open citation signal is essentially flat, down from 9.43 in 2023 to 9.40 in 2024. That stability matters. It suggests the journal is not in a collapse or a surge phase. It is holding a strong mature position.

For authors, that usually means the editorial identity is stable too. The journal still expects flagship-level field consequence rather than just decent disease-level efficacy.

The common mistake is to see a strong JIF, recognize the prestige of the Molecular Therapy family, and assume any good gene-therapy or cell-therapy paper should be competitive here.

That is not how the journal frames itself. Its public materials emphasize research in gene transfer, vector design, stem cell manipulation, and multiple therapeutic modalities for genetic and acquired disease. That is broader than one disease area and more demanding than one promising preclinical result.

In practice, the journal tends to reward manuscripts where:

• the platform or therapeutic logic matters beyond one model
• the translational claim matches the evidence
• the delivery, mechanism, or engineering layer is load-bearing
• the paper feels like a flagship family owner, not just a family-branded target

That means the metric tells you the journal has weight. It does not tell you that a disease-specific efficacy paper belongs there.

In our pre-submission review work on manuscripts targeting Molecular Therapy, the repeat problem is not low ambition. It is miscalibrated ambition.

We see papers that are genuinely good but still more disease-specific than platform-relevant. Editors actually screen for that difference, and the public journal materials make the field-level expectation clear.

In our pre-submission review work on manuscripts targeting Molecular Therapy, four failure patterns recur.

The study has efficacy without enough field advance. The therapy works in one model, but it does not yet change how the broader field thinks about delivery, engineering, safety, or therapeutic logic.

The translational promise outruns the package. We often see strong top-line efficacy with missing durability, safety, manufacturability, or mechanism.

The platform contribution is weaker than the disease story. That is often a sign the paper belongs in a disease journal rather than the flagship therapeutic owner.

The manuscript is really for a narrower family title. The work may fit the Molecular Therapy family well, just not necessarily the flagship journal.

If that sounds like the paper, a Molecular Therapy submission readiness check is usually more useful than another round of line editing.

The impact factor does not tell you whether the platform consequence is strong enough, whether the translational package is complete enough, or whether the flagship journal is the right owner rather than a narrower family title.

That is where most mismatches happen. The metric places the journal. It does not widen the field consequence of the paper.